Summary
The aim of this investigation was to assess the pharmacokinetics and bioavail-ability of methylergometrine in 6 healthy male volunteers after an oral dose of 0.125mg and after an intravenous dose of 0.200mg. A large variation in bio-availability of between 22 and 136% (mean value 84.9 ± 37.2%) was observed in the 6 volunteers. The lag time was also subject-dependent and ranged between 0.24 and 0.50 hours. After intravenous administration, the pharmacokinetic profile could be described with a 2-compartment model. The distribution half-life (t½α) was 0.19 ± 0.27 hours, the elimination half-life (β) was 1.85 ± 0.28 hours, total body clearance (CL) amounted to 34.1 ± 9.7 L/ h, and the steady-state volume of distribution (Vss) was 71.5 ± 25.9L. After oral administration, the pharmacokinetic profile could be described with a 1 -compartment model. The absorption half-life (t½abs) was 0.08 ± 0.08 hours, and the elimination half-life (t½β) was 2.08 ± 0.43 hours. This study with oral methylergometrine demonstrated such large interindividual variability in bioavailability that from a pharmacokinetic point of view the oral route of administration does not appear to be the most reliable way for accurate dosing in the prevention of postpartum haemorrhage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
van Dongen PWJ, Roosmalen J van, Boer CN de, et al. Oxyto-cics for the prevention of post partum haemorrhages, a review. Pharm Weekbl 1991; 13: 238–43
Prendiville WJ, Harding JE, Elbourne DR, et al. The Bristol third stage trial: active versus physiological management of third stage of labour. BMJ 1988; 297: 1295–300
Royston E, Armstrong S. Preventing maternal deaths. World Health Organization, Geneva, 1989
Hogerzeil HV, Goeje MJ de, Abu-Reid IO. Stability of essential drugs in Sudan. Lancet 1991; 338: 754–5
Hogerzeil HV, Battersby A, Srdanovic V, et al. Stability of essential drugs during shipment to the tropics. BMJ 1992; 304: 210–2
Walker GJA, Hogerzeil HV, Lindgren U. Potency of ergomet-rine in tropical countries. Lancet 1988; 2: 393
Anonymous. Ergot alkaloids and derivatives. In: Reynolds JF, editor. Martindale. The Extra Pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989: 1051-959
Rall TW, Schleifer LS. Drugs affecting uterine motility. Oxyto-cin, Prostaglandins, ergot alkaloids, tocolytic agents. In: Goodman and Gilman, editors. The pharmaceutical basis of therapeutics. 7th ed. [Chap 39] New York: MacMillan Publishing Company, 1985: 928–45
Mäntylä R, Kleimola T, Kanto J. Methylergometrine concentrations in the human plasma and urine. Int J Clin Pharmacol Bio 1978; 16: 254–7
Mäntylä R, Kanto J. Clinical pharmacokinetics of methylergometrine (methylergonovine). Int J Clin Pharmacol TherToxicol 1981; 19: 386–91
de Groot ANJA, Vree TB, Hekster YA, et al. Pharmacokinetics and bioavailability of oral ergometrine in male volunteers. Biopharm Drug Dispos 1994; 15: 65–73
de Groot ANJA, Vree TB, Hekster YA, et al. High performance liquid chromatography of ergometrine and preliminary pharmacokinetics in plasma of men. J Chromatogr 1993; 613: 158–61
Proost JH, Meyer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155–63
Bredberg U, Eyjolfsdottir GS, Paalzow L, et al. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Euro J Clin Pharmacol 1986; 30: 75–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Groot, A.N.J.A., Vree, T.B., Hekster, Y.A. et al. Variation in Bioavailability of Oral Methylergometrine in Healthy Male Volunteers. Drug Invest 8, 345–351 (1994). https://doi.org/10.1007/BF03257449
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257449